Michaelis B, Levy J A
Cancer Research Institute, University of California, School of Medicine, San Francisco 94143.
AIDS. 1989 Jan;3(1):27-31.
Recombinant human interferon beta (rIFN-beta) reduces replication of HIV in cultured peripheral mononuclear cells. The effect is most pronounced when high levels of the drug are employed. Maintenance of the rIFN-beta in culture is required since removal of the agent generally leads to a return of virus production by the infected cells. Moreover, at low concentrations of the drug, a breakthrough in HIV replication is observed. High concentrations of the rIFN-beta (greater than 100 units/ml) were cytotoxic for transformed T cells. This latter observations suggests that rIFN-beta might be useful in human T-cell malignancies. Beta interferon therefore might be useful for the treatment of HIV infection, particularly since side effects of the drug are limited in treated individuals.
重组人干扰素β（rIFN-β）可降低HIV在培养的外周血单个核细胞中的复制。当使用高剂量药物时，这种效果最为明显。由于去除该药物通常会导致受感染细胞恢复病毒产生，因此需要在培养物中维持rIFN-β。此外，在低浓度药物时，可观察到HIV复制的突破。高浓度的rIFN-β（大于100单位/毫升）对转化的T细胞具有细胞毒性。后一观察结果表明，rIFN-β可能对人类T细胞恶性肿瘤有用。因此，β干扰素可能对治疗HIV感染有用，特别是因为该药物在治疗个体中的副作用有限。
